Plasma immunoreactive IX-atrial natriuretic peptide (IR IX-ANP) levels were determined before, and at 5 and 10 min after bolus intravenous administration of morphine (0,15 or O'30 mg/kg) in 21 otherwise healthy human subjects who underwent elective surgery. Five min after injection IR IX-ANP levels had nearly doubled in response to both doses of morphine. At 10 min, plasma IR IX-ANP concentrations were lower than at 5 min in the 0·15 mg/kg group suggesting that IR IX-ANP levels peak shortly after morphine administration. Morphine has been widely used in the treatment of acute left ventricular failure and ANP is a recently discovered hormone which possesses unique favourable effects in patients with congestive heart failure when administered exogenously. The combination of these data suggests an important potential role for ANP in the mechanism of action of morphine in the treatment of acute left ventricular failure.
Additional key phrases: heart failure; acute left ventricular failure Atrial natriuretic peptide (ANP) is a recently discovered hormone I that apparently plays a role in the regulation of extracellular volume. The peptide induces increases in sodium and water excretion and glomerular filtration rate. ANP has also been reported to exert a marked influence on cardiovascular function (recently reviewed by Goetz') . Indeed, several in vitro and in vivo studies have indicated that atrial natriuretic peptide is a potent peripheral vasodilator'? and reduces cardiac output by lowering venous return."
Morphine has been widely used in the treatment of pulmonary oedema following acute left ventricular failure. The mechanism of this favourable effect has not been completely resolved. Laboratory and clinical investigations suggests that the major benefit is due to reductions in ventricular afterload and preload as a result of decreased peripheral resistance and increased capacity of the peripheral vascular compartments, respectively.?" Bolus injections and infusions of ANP have been reported to have beneficial effects on cardiac performance in patients with congestive heart failure. I D-12 Morphine has been shown previously to increase ANP concentrations in rat plasma." Correspondence: Dr Tomris Ozben, Akdeniz Oniversitesi TIp Fakiiltesi, Topcular 07059, Antalya, Turkey.
Two key questions are raised by these findings. Does morphine increase the ANP plasma levels in humans? If so, is this effect linked to some cardiovascular actions of morphine, especially in acute left ventricular failure? The objective of the present study was to answer the first question by determining changes in plasma levels of ANP after morphine administration in humans.
MATERIALS AND METHODS

Subjects
Twenty one ASA physical status I patients aged 20-50 years who were scheduled for various types of elective surgery were included in this study. Informed consent was obtained from all the patients. Preoperative biochemical findings (glucose, BUN, creatinine, total bilirubin, AL T, AST and cholesterol) were normal. The patients were not premedicated.
Study protocol
The patients were divided into two groups according to the choice of morphine dose (0·15 mgt kg or O' 30 mg/kg). There were no significant differences in age, weight and sex between the groups (Table 1) . After the patients had been at least 30 min in the supine position both antecubital veins were cannulated and an (jgulman et 01. intravenous bolus of morphine (0,15 mg/kg or 0'30mg/kg) was administered. Venous blood (IOmL/sample) was drawn from the contralateral vein just before the morphine administration and at 5 and 10min thereafter. Surgical interventions were carried out under general anaesthesia following this procedure.
Determination of ANP Plasma IR oc-ANP levels were assayed using the commercial human oc-ANP[ 1241] RIA system kits purchased from Amersham International pic (Aylesbury, Bucks, UK). In summary, IOmL amounts of blood were collected in plastic tubes containing in final concentration: EDTA I mgt ml., pepstatin 5 JlM, phenyl-methyl sulphonyl fluoride 10JlM, aprotinin (Trasylol) 500 KIU/mL and soya bean trypsin inhibitor 50 BAEE II/mL. and were immediately placed on ice until being centrifuged at 3000g, 4°C for 30 min. Separated
Values are expressed as mean ± SEM. plasma samples were stored at -30°C. On day I of the assay, within 2 weeks of sampling, plasma samples were thawed, centrifuged and extracted through C-18 cartridges (Arnprep, Amersham). Alpha-ANP elution was achieved using aqueous acidic ethanol. Plasma extracts or oc-ANP standards, 100JlL, were incubated in duplicate with antibody for 24h at 4°C. On day 2, 100JlL of (3_[ml] iodotyrosyl"') IX-ANP was added to all tubes, and after 24 h incubation at 4°C. 250 JlL Amerlex-M second antibody reagent was pipetted into each tube. After incubation at room temperature for 10min separation of the antibody-bound fraction was achieved with an Amerlex-M separator. The radioactivity present in the tubes was determined by counting for 60 s in a f scintillation counter (OPe Gambyt). The recovery of the extraction procedure was 77 ± 4·1 % (mean ± SEM) as determined by addition of synthetic human IX-ANP to plasma. Inter-assay and intra-assay variations were 12% and 9%, respectively.
Statistical analysis
Data are expressed as mean ± SEM. Statistical comparisons within each group were performed using the paired r-test. To compare the differences between groups, Student's r-test was used. Significance was accepted at the P < 0·05 level. 
RESULTS
The effects of 0·15 and 0·30 rng/kg intravenous morphine on the plasma IR (X-ANP concentrations are presented in Fig. I . Both doses of morphine significantly increased the level of ANP in plasma. We observed no significant differences between plasma ANP values at 5 min and 10min after O'30 mg/kg morphine injection, but 5 min after 0·15 mg/kg morphine, plasma ANP values were significantly higher than the values determined 10min after injection (P < 0'05). The effects of the two doses of morphine did not differ significantly, although plasma ANP concentrations showed a tendency to return to control values more rapidly in the group given the lower dose.
DISCUSSION
We observed that, in accordance with the results in rats, morphine increased the plasma levels of IR (X-ANP in humans. In rats, morphine (100 mgt kg, intraperitoneally) increased the circulating levels of IR-ANF up to 50-fold,13 whereas in humans we observed a 2-fold increase in the dose-range used in this study.
The lack of differences between the effects of 0·15 and O' 30 mg/kg morphine might suggest that the maximal efficacy was reached. Nevertheless, it remains to be established whether higher doses of morphine cause greater increases in the plasma ANP level in humans.
There is general agreement that only large doses of ANP cause a prompt and substantial increase in urine flow and sodium excretion. Infusion rates that increase plasma ANP levels twofold (levels which we observed in our study produce only modest natriuresis and diuresis or in some cases no response at all.2 This fact may explain the observation that morphine administration causes no brisk diuresis in humans. Indeed, the well known and studied effect of morphine is anti-diuresis which has been attributed to enhanced vasopressin secretion. 14. 15 However, there is strong evidence which indicates that other mechanisms also play a role. I 6-18 The 50-fold increase in ANP levels observed after 100mg/kg morphine in ratsIJ should stimulate urine flow. Of particular interest is the observation that in non-hydrated rats morphine caused diuresis whereas the same doses produced anti diuresis in rats hydrated with water. 19. 20 These opposite effects may be related to the depletion of ANP stores after water loading. The diuresis observed in rats after morphine administration is transient and has been attributed to the temporary inhibition of vasopressin release." Interestingly, a diuretic effect of selective K receptor agonists in normally hydrated rats" and primates" has been reported, an effect which was also linked to the supression of vasopressin release. Thus, it is not surprising that other investigators found ANP levels not to be changed by selective J1. receptor agonists." Furthermore, ANP has been shown to inhibit the secretion of vasopressin."
ANP is vasoactive and induces a number of cardiovascular changes including decreases in arterial blood pressure and cardiac output, and a translocation of fluid from plasma to the interstitial fluid space. ' In human subjects, intravenously administered ANP causes cutaneous vasodilatiorr' and infusion of ANP into the brachial artery induces a reduction in forearm vascular resistance. ' The decrease in cardiac filling pressure, or preload, appears to be primarily responsible for the decrease in cardiac output, and may result from increased resistance to venous return, not from venous dilation." ANP exhibits a predilection for inhibiting the effects of angiotensin II compared with norepinephrine." It is conceivable therefore that relatively low plasma levels of ANP may possess substantial vasodilator efficacy under conditions in which elevated peripheral resistance is sustained by the renin-angiotensin system. Indeed, the patients with congestive heart failure whose haemodynamic state is characterised by a markedly increased systemic resistance demonstrated a significant reduction of systemic vascular resistance and an increase in cardiac output after bolus injections or intravenous infusions of ANP. Il H 2 Increased circulating levels of endogenous ANP in patients with heart failure have been reported. 10. 11.26 In conclusion, morphine produces increases in IR (X-ANP levels in humans. It would be premature to consider that this effect is linked to the beneficial cardiovascular actions of morphine in patients with acute heart failure because the significance of ANP levels observed in this study and the changes in plasma ANP levels after morphine administration in patients with acute left ventricular failure are unknown.
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